



Mebiopharm Co.,Ltd.  
Holland Hills 14<sup>th</sup> Floor  
5-11-2 Toranomom, Minato-ku  
Tokyo 105-0001 Japan  
Phone +81-3-5777-2626 FAX +81-3-5777-2628

June 10, 2011

## **Mebiopharm applies for listing on TOKYO AIM**

Mebiopharm Co., Ltd. (“Mebiopharm”) announces today that the company has applied for listing on TOKYO AIM, having appointed Phillip Securities Japan, Ltd. (“Phillip Securities”) as its Japanese Nominated Adviser’ (J-Nomad).

TOKYO AIM is a new market for professional investors jointly established by Tokyo Stock Exchange and London Stock Exchange. It has a large potential to provide growing companies effective and flexible capital raising opportunities. Phillip Securities is part of Phillip Capital Group, headquartered in Singapore and operating in ten countries across the world. It has broad experience in major Asian capital markets.

Since its establishment in 2002, Mebiopharm has developed NCEs (New Chemical Entities) focusing on cancer treatment, aiming to deliver it to the market. Based on the technology created in Japan, it has conducted research, development and clinical trials in the United States and other countries.

With this application for a listing on TOKYO AIM, Mebiopharm is entering a new stage in its corporate development, utilizing this new market to obtain financing for its future growth.

Mebiopharm is planning to use the proceeds of its listing on TOKYO AIM to finance the expansion of its research, development and global activities.



Mebiopharm Co.,Ltd.  
Holland Hills 14<sup>th</sup> Floor  
5-11-2 Toranomon, Minato-ku  
Tokyo 105-0001 Japan  
Phone +81-3-5777-2626 FAX +81-3-5777-2628

**About TOKYO AIM, Inc.:**

TOKYO AIM, Inc. was jointly established 2009 by the Tokyo Stock Exchange Group, Inc. (51%) and the London Stock Exchange plc (49%). TOKYO AIM, the equity market for professional investors which it operates, was established following the revision of the Japanese Financial Instruments and Exchange Act in 2008, employing a new structural framework with greater flexibility. The new bond market for professional investors, TOKYO PRO-BOND Market is established alongside the TOKYO AIM stock market, which allows for flexible and timely bond issuances. TOKYO AIM Inc. provides new avenues for capital raising for companies in Japan and Asia and responds to various needs of professional investors through its equity and bond markets.

Website: <http://www.tokyo-aim.com>

**About Phillip Securities:**

Phillip Securities is part of the Phillip Capital Group, an international financial group headquartered in Singapore with operations in ten countries around the world. Phillip Capital Group is one of the leading financial services providers in Singapore, Hong Kong and other major Asian markets, and as a group holds over USD 1 billion in equity capital, and more than USD 18 billion in assets under management. The group has over 3,500 employees worldwide, and provides comprehensive financial services to more than 720,000 corporate and individual customers. Capitalizing on its network and expertise in Asia, Phillip Securities in Japan offers a wide range of financial products including Japanese stocks, Asian stocks with strong growth potential, investment trusts, foreign bonds, FX and futures, through both online and face-to-face sales channels. For details see the company's website: <http://www.phillip.co.jp/>

**About J-Nomad:**

TOKYO AIM employs a J-Nomad system based on the Nomad (Nominated Advisor) model developed for the London Stock Exchange's AIM market. The J-Nomad plays a central role in TOKYO AIM's regulatory model, as it confirms the overall appropriateness and suitability of the company to list on the market and provides advice and guidance in respect of compliance with the TOKYO AIM's rules and information disclosure on an ongoing basis. Currently, seven companies are designated as J-Nomads for TOKYO AIM.

**About Mebiopharm Co., Ltd.:**

Mebiopharm was established on July 15, 2002 aiming to market a NCE which applied the technology of DDS (drug delivery system) to a blockbuster for colorectal cancer first line treatment regimen in Europe and the United States.

DDS technology, as represented by liposome, is the core of Mebiopharm's activities. Focused on anticancer drugs, Mebiopharm endeavors day and night to bring its innovative DDS technology to actual medical treatments as soon and effectively as possible.

One of Mebiopharm's pipeline products, MBP-426, Oxaliplatin encapsulated liposome, is in Phase II clinical trial for 2<sup>nd</sup> line Gastric and GE-junction cancer treatment in the United States. MBP-426 is also planned to start its Phase II clinical trials for colorectal cancer treatment.

Website: <http://www.mebiopharm.com/english>